Literature DB >> 3313220

Cystic fibrosis: a review of pulmonary infections and interventions.

M J Thomassen1, C A Demko, C F Doershuk.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3313220     DOI: 10.1002/ppul.1950030510

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


× No keyword cloud information.
  21 in total

1.  Characterization of alginate lyase from Pseudomonas syringae pv. syringae.

Authors:  L A Preston; T Y Wong; C L Bender; N L Schiller
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

2.  Microbiological processing of respiratory specimens from patients with cystic fibrosis.

Authors: 
Journal:  Can J Infect Dis       Date:  1993-05

3.  Heterogeneity, persistence, and distribution of Pseudomonas aeruginosa genotypes in cystic fibrosis patients.

Authors:  M Fegan; P Francis; A C Hayward; J A Fuerst
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

4.  Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa.

Authors:  R A Hatch; N L Schiller
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  Proteus mirabilis as a cause of recurrent lung infection in a cystic fibrosis patient.

Authors:  M Ojeda-Vargas; A Pacheco; M Elia; R Villaverde; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-03       Impact factor: 3.267

6.  Raised serum soluble interleukin-2 receptor concentrations in cystic fibrosis patients with and without evidence of lung disease.

Authors:  E Dagli; J A Warner; C R Besley; J O Warner
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

7.  Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis.

Authors:  M R Shreve; S Butler; H J Kaplowitz; H R Rabin; D Stokes; M Light; W E Regelmann
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 8.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

9.  Characterization of the Pseudomonas aeruginosa alginate lyase gene (algL): cloning, sequencing, and expression in Escherichia coli.

Authors:  N L Schiller; S R Monday; C M Boyd; N T Keen; D E Ohman
Journal:  J Bacteriol       Date:  1993-08       Impact factor: 3.490

Review 10.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.